RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells) And no ... ONCY will NOT be dealing with a different patient population. ONCY will be dealing with the same patient population who have failed a 2nd line breast cancer therapy, whether it was CDK4,6 inhibitors or ADC Enhertu, whose active payload is a chemotherapy - the same therapies that pelareorep was up against in various other completed ONCY trials in which pelareorep had successfully achieved effective results. So those patients who have failed Enhertu will have been already identified as eligible pelareorep ready patients. Consequently clinical trial enrollment should be relatively easy by ONCY or the Big Pharma who acquires ONCY and runs the trial for an accretive Accelerated Approval and followed by a full approval on the same trial data.